Basilea Pharmaceutica AG Share Price
Stocks
BSLN
CH0011432447
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.60 CHF | +0.57% |
|
+1.54% | -3.84% |
| Market Cap | 652M 798M 701M 598M 1.12B 76.87B 1.14B 7.74B 3.02B 37.79B 3B 2.93B 131B | P/E 2026 * |
14x | P/E 2027 * | 18.3x |
|---|---|---|---|---|---|
| Enterprise Value | 500M 612M 537M 459M 862M 58.92B 875M 5.93B 2.32B 28.97B 2.3B 2.25B 100B | EV / Sales 2026 * |
1.9x | EV / Sales 2027 * | 1.64x |
| Free-Float |
91.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Basilea Pharmaceutica AG
| 1 day | +0.57% | ||
| 1 week | +1.54% | ||
| Current month | -1.50% | ||
| 1 month | +1.35% | ||
| 3 months | -0.75% | ||
| 6 months | -6.07% | ||
| Current year | -3.84% |
| 1 week | 51 |  | 52.7 |
| 1 month | 50.4 | | 56.3 |
| Current year | 47.8 | | 59.2 |
| 1 year | 44.7 | | 59.7 |
| 3 years | 32 | | 59.7 |
| 5 years | 29.55 | | 59.7 |
| 10 years | 29.28 | | 95.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 61 | 18/04/2018 |
Adesh Kaul
DFI | Director of Finance/CFO | 52 | 09/04/2019 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 62 | 30/04/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Werner
BRD | Director/Board Member | 70 | 28/11/2011 |
| Chairman | 71 | 08/04/2013 | |
Nicole Onetto
BRD | Director/Board Member | 73 | 26/04/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 29/05/26 | Sell | -400 | 0.0030% | |||
| 13/05/26 | Sell | -1,043 | 0.0078% | |||
| 04/05/26 | Sell | 400 | 0.0030% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.57% | +1.54% | -4.54% | +23.91% | 798M | |
| +1.07% | -3.49% | -3.25% | +12.87% | 46.86B | |
| +0.25% | +1.65% | +408.41% | +629.49% | 40.23B | |
| -0.27% | +4.45% | +9.93% | +66.92% | 36.23B | |
| +0.35% | +0.87% | +3.60% | -8.81% | 34.72B | |
| +3.14% | +1.02% | +3.37% | +38.15% | 27.89B | |
| -0.73% | +11.84% | +31.97% | +143.53% | 16.79B | |
| +0.47% | -2.74% | - | - | 16.74B | |
| +0.42% | -5.52% | +0.76% | +8.50% | 13.12B | |
| -2.68% | -2.49% | -15.00% | -31.68% | 12.7B | |
| Average | +0.26% | +0.90% | +48.36% | +98.10% | 24.61B | |
| Weighted average by Cap. | +0.48% | +0.92% | +75.04% | +136.25% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 263M 322M 283M 241M 453M 31B 460M 3.12B 1.22B 15.24B 1.21B 1.18B 52.69B | 267M 327M 288M 245M 461M 31.53B 468M 3.18B 1.24B 15.5B 1.23B 1.2B 53.6B |
| Net income | 51.57M 63.13M 55.45M 47.32M 88.91M 6.08B 90.28M 612M 239M 2.99B 237M 232M 10.33B | 39.24M 48.04M 42.19M 36.01M 67.66M 4.63B 68.7M 466M 182M 2.27B 180M 176M 7.86B |
| Net Debt | -152M -186M -164M -140M -263M -17.95B -267M -1.81B -706M -8.83B -700M -685M -30.51B | -213M -260M -229M -195M -367M -25.06B -372M -2.52B -986M -12.32B -977M -956M -42.6B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/07/26 | CHF 52.60 | +0.57% | 15,429 |
| 23/07/26 | CHF 52.30 | 0.00% | 10,213 |
| 22/07/26 | CHF 52.30 | -0.19% | 17,109 |
| 21/07/26 | CHF 52.40 | +1.75% | 16,403 |
| 20/07/26 | CHF 51.50 | -0.58% | 13,778 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BSLN Stock
Select your edition
All financial news and data tailored to specific country editions
